Replies to post #2770 on Biotech Values

[poorgradstudent]

Not to belabour the point, but if we start to consider additional trials as part of the pipeline, then i can name many companies that have large pipelines :-)

For example, master named avastin in metastatic breast cancer as one of the pipeline events. Avastin has already failed in one metastatic breast cancer setting, so it becomes hard to consider another avastin breast cancer trial in another setting as part of a promising pipeline.

I don't doubt the financial impact that label expansion can have for the company. It's a personal semantics thing, but i just don't consider these label expansions as the pipeline. I'm putting my foot down on this one... :-)